Retrospective Application of Population Pharmacokinetic Model-Based Dosing for Fludarabine in Allogeneic Hematopoietic Cell Transplant for Inborn Errors of Immunity | Synapse
March 3, 2026
Retrospective Application of Population Pharmacokinetic Model-Based Dosing for Fludarabine in Allogeneic Hematopoietic Cell Transplant for Inborn Errors of Immunity
Key Points
Effective fludarabine dosing is achieved through population pharmacokinetic modeling, optimizing treatment.
The analysis includes data from multiple patients with inborn errors of immunity, enhancing reliability.
Retrospective analysis of pharmacokinetic data supports personalized dosing strategies in hematopoietic cell transplants.
These findings emphasize the need for tailored treatments to improve outcomes in immunocompromised patients.